ParkinsonCanadaV1, Main, Exploration, bibRecord, 003C35

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease

Identifieur interne : 003C35 ( Main/Exploration ); précédent : 003C34; suivant : 003C36

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease

Auteurs : I. H. Richard [États-Unis] ; R. Kurlan [États-Unis] ; C. Tanner [États-Unis] ; S. Factor [États-Unis] ; J. Hubble [États-Unis] ; O. Suchowersky [Canada] ; C. Waters [États-Unis]

Source :

Neurology [ 0028-3878 ] ; 1997.

RBID : Pascal:97-0269409

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Sélégiline, Antiparkinsonien, IMAO B, Antidépresseur, Questionnaire, Toxicité, Association médicamenteuse, Fréquence, Homme, Sérotonine syndrome.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antidepressant agent, Antiparkinson agent, Drug combination, Frequency, Human, MAO B inhibitor, Parkinson disease, Questionnaire, Selegiline, Toxicity.

Abstract

Article abstract-The manufacturer of deprenyl (selegeline; Eldepryl) (Somerset Pharmaceuticals, Tampa, FL) recently advised physicians to avoid prescribing the drug in combination with an antidepressant because of potentially serious CNS toxicity that may represent the serotonin syndrome. Manifestations of the serotonin syndrome vary but may include changes in mental status and motor and autonomic function. To better estimate the frequency of the serotonin syndrome in patients with Parkinson's disease (PD) treated with deprenyl and an antidepressant, we surveyed all investigators in the Parkinson Study Group. Based on estimates provided by the 47 investigators (75%) who responded, 4,568 patients were treated with the combination of deprenyl and an antidepressant medication. Eleven patients (0.24%) were reported to have experienced symptoms possibly consistent with the serotonin syndrome. Only two patients (0.04%) experienced symptoms considered to be serious. No deaths were reported. We also reviewed all published case reports and adverse experiences reported to the U.S. Food and Drug Administration and the manufacturer of Eldepryl. Available information indicates that serious adverse experiences resulting from the combined use of deprenyl and an antidepressant medication in patients with PD are quite rare and that the frequency of the true "serotonin syndrome" is even rarer.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000E93
to stream PascalFrancis, to step Curation: 001030
to stream PascalFrancis, to step Checkpoint: 000D53
to stream Main, to step Merge: 004288
to stream Main, to step Curation: 003C35

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease</title>
<author><name sortKey="Richard, I H" sort="Richard, I H" uniqKey="Richard I" first="I. H." last="Richard">I. H. Richard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of RochesterRochester, NY</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of RochesterRochester, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kurlan, R" sort="Kurlan, R" uniqKey="Kurlan R" first="R." last="Kurlan">R. Kurlan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of RochesterRochester, NY</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of RochesterRochester, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tanner, C" sort="Tanner, C" uniqKey="Tanner C" first="C." last="Tanner">C. Tanner</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>The Parkinson's Institute</s1>
<s2>Sunnyvale, CA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>The Parkinson's Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Factor, S" sort="Factor, S" uniqKey="Factor S" first="S." last="Factor">S. Factor</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Albany Medical College</s1>
<s2>Albany, NY</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Albany Medical College</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hubble, J" sort="Hubble, J" uniqKey="Hubble J" first="J." last="Hubble">J. Hubble</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Ohio State University</s1>
<s2>Columbus, OH</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Ohio State University</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Suchowersky, O" sort="Suchowersky, O" uniqKey="Suchowersky O" first="O." last="Suchowersky">O. Suchowersky</name>
<affiliation wicri:level="4"><inist:fA14 i1="05"><s1>University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
<orgName type="university">Université de Calgary</orgName>
</affiliation>
</author>
<author><name sortKey="Waters, C" sort="Waters, C" uniqKey="Waters C" first="C." last="Waters">C. Waters</name>
<affiliation wicri:level="4"><inist:fA14 i1="06"><s1>University of Southern California</s1>
<s2>Los Angeles, CA</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Los Angeles</settlement>
<region type="state">Californie</region>
</placeName>
<orgName type="university">Université de Californie du Sud</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">97-0269409</idno>
<date when="1997">1997</date>
<idno type="stanalyst">PASCAL 97-0269409 INIST</idno>
<idno type="RBID">Pascal:97-0269409</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E93</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001030</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000D53</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000D53</idno>
<idno type="wicri:doubleKey">0028-3878:1997:Richard I:serotonin:syndrome:and</idno>
<idno type="wicri:Area/Main/Merge">004288</idno>
<idno type="wicri:Area/Main/Curation">003C35</idno>
<idno type="wicri:Area/Main/Exploration">003C35</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease</title>
<author><name sortKey="Richard, I H" sort="Richard, I H" uniqKey="Richard I" first="I. H." last="Richard">I. H. Richard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of RochesterRochester, NY</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of RochesterRochester, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kurlan, R" sort="Kurlan, R" uniqKey="Kurlan R" first="R." last="Kurlan">R. Kurlan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of RochesterRochester, NY</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of RochesterRochester, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tanner, C" sort="Tanner, C" uniqKey="Tanner C" first="C." last="Tanner">C. Tanner</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>The Parkinson's Institute</s1>
<s2>Sunnyvale, CA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>The Parkinson's Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Factor, S" sort="Factor, S" uniqKey="Factor S" first="S." last="Factor">S. Factor</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Albany Medical College</s1>
<s2>Albany, NY</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Albany Medical College</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hubble, J" sort="Hubble, J" uniqKey="Hubble J" first="J." last="Hubble">J. Hubble</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Ohio State University</s1>
<s2>Columbus, OH</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Ohio State University</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Suchowersky, O" sort="Suchowersky, O" uniqKey="Suchowersky O" first="O." last="Suchowersky">O. Suchowersky</name>
<affiliation wicri:level="4"><inist:fA14 i1="05"><s1>University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Calgary</settlement>
<region type="state">Alberta</region>
</placeName>
<orgName type="university">Université de Calgary</orgName>
</affiliation>
</author>
<author><name sortKey="Waters, C" sort="Waters, C" uniqKey="Waters C" first="C." last="Waters">C. Waters</name>
<affiliation wicri:level="4"><inist:fA14 i1="06"><s1>University of Southern California</s1>
<s2>Los Angeles, CA</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Los Angeles</settlement>
<region type="state">Californie</region>
</placeName>
<orgName type="university">Université de Californie du Sud</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="1997">1997</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antidepressant agent</term>
<term>Antiparkinson agent</term>
<term>Drug combination</term>
<term>Frequency</term>
<term>Human</term>
<term>MAO B inhibitor</term>
<term>Parkinson disease</term>
<term>Questionnaire</term>
<term>Selegiline</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Sélégiline</term>
<term>Antiparkinsonien</term>
<term>IMAO B</term>
<term>Antidépresseur</term>
<term>Questionnaire</term>
<term>Toxicité</term>
<term>Association médicamenteuse</term>
<term>Fréquence</term>
<term>Homme</term>
<term>Sérotonine syndrome</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Article abstract-The manufacturer of deprenyl (selegeline; Eldepryl) (Somerset Pharmaceuticals, Tampa, FL) recently advised physicians to avoid prescribing the drug in combination with an antidepressant because of potentially serious CNS toxicity that may represent the serotonin syndrome. Manifestations of the serotonin syndrome vary but may include changes in mental status and motor and autonomic function. To better estimate the frequency of the serotonin syndrome in patients with Parkinson's disease (PD) treated with deprenyl and an antidepressant, we surveyed all investigators in the Parkinson Study Group. Based on estimates provided by the 47 investigators (75%) who responded, 4,568 patients were treated with the combination of deprenyl and an antidepressant medication. Eleven patients (0.24%) were reported to have experienced symptoms possibly consistent with the serotonin syndrome. Only two patients (0.04%) experienced symptoms considered to be serious. No deaths were reported. We also reviewed all published case reports and adverse experiences reported to the U.S. Food and Drug Administration and the manufacturer of Eldepryl. Available information indicates that serious adverse experiences resulting from the combined use of deprenyl and an antidepressant medication in patients with PD are quite rare and that the frequency of the true "serotonin syndrome" is even rarer.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>États-Unis</li>
</country>
<region><li>Alberta</li>
<li>Californie</li>
</region>
<settlement><li>Calgary</li>
<li>Los Angeles</li>
</settlement>
<orgName><li>Université de Calgary</li>
<li>Université de Californie du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Richard, I H" sort="Richard, I H" uniqKey="Richard I" first="I. H." last="Richard">I. H. Richard</name>
</noRegion>
<name sortKey="Factor, S" sort="Factor, S" uniqKey="Factor S" first="S." last="Factor">S. Factor</name>
<name sortKey="Hubble, J" sort="Hubble, J" uniqKey="Hubble J" first="J." last="Hubble">J. Hubble</name>
<name sortKey="Kurlan, R" sort="Kurlan, R" uniqKey="Kurlan R" first="R." last="Kurlan">R. Kurlan</name>
<name sortKey="Tanner, C" sort="Tanner, C" uniqKey="Tanner C" first="C." last="Tanner">C. Tanner</name>
<name sortKey="Waters, C" sort="Waters, C" uniqKey="Waters C" first="C." last="Waters">C. Waters</name>
</country>
<country name="Canada"><region name="Alberta"><name sortKey="Suchowersky, O" sort="Suchowersky, O" uniqKey="Suchowersky O" first="O." last="Suchowersky">O. Suchowersky</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C35 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003C35 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:97-0269409
   |texte=   Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri